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Abstract
Objective: To report pediatric cases of paradoxical respiratory adverse drug reactions (ADRs) after exposure to oral
mucolytic drugs (carbocysteine, acetylcysteine) that led to the withdrawal of licenses for these drugs for infants in France
and then Italy.
Design: The study followed the recommendations of the European guidelines of pharmacovigilance for medicines used in
the paediatric population.
Setting: Cases voluntarily reported by physicians from 1989 to 2008 were identified in the national French
pharmacovigilance public database and in drug company databases.
Patients: The definition of paradoxical respiratory ADRs was based on the literature. Exposure to mucolytic drugs was
arbitrarily defined as having received mucolytic drugs for at least 2 days (.200 mg) and at least until the day before the first
signs of the suspected ADR.
Results: The non-exclusive paradoxical respiratory ADRs reported in 59 paediatric patients (median age 5 months, range 3
weeks to 34 months, 98% younger than 2 years old) were increased bronchorrhea or mucus vomiting (n=27), worsening of
respiratory distress during respiratory tract infection (n=35), dyspnoea (n=18), cough aggravation or prolongation (n=11),
and bronchospasm (n=1). Fifty-one (86%) children required hospitalization or extended hospitalization because of the ADR;
one patient died of pulmonary oedema after mucus vomiting.
Conclusion: Parents, physicians, pharmacists, and drug regulatory agencies should know that the benefit risk ratio of
mucolytic drugs is at least null and most probably negative in infants according to available evidence.
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Introduction
Cysteine derivatives (carbocysteine, acetylcysteine) are mucolytic
drugs that act by breaking disulphide bridges between macromol-
ecules and lead to reduced mucus viscosity in the respiratory tract
[1]. These derivatives are widely used for paediatric patients to treat
acute respiratory tract infections such as bronchitis, bronchiolitis, or
productive cough. They are some of the most prescribed medicines
for children, particularly infants in European countries such as The
Netherlands [2], Italy [3], Spain [4], France [5–7], and Germany
[8], and in Brazil [9] and African countries [10].
Several alerts have concerned the safety and benefit risk ratio of
cough medicines for children, particularly during recent years. In
January 2008, the US Food and Drug Administration recommended
not to use over-the-counter medicines for children under 2 years old,
particularly medicines for cough and cold, because of serious and
potentially life-threatening side effects [11]. In 2010, the French drug
agency, and then the Italian drug agency, withdrew the licenses for
children younger than 2 years old for carbocysteine and acetylcysteine
because their use was associated with paradoxically increased
bronchorrhea and acute respiratory distress during respiratory tract
infections [12–14]. However, published data on these paradoxical
adverse drug reactions (ADRs) are limited to short hospital-based
studies with a very small number of cases (n=6) [12] or were simply
mentioned in the discussion of a Cochrane database systematic review
without description of cases [13].
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used to treat acute cough in infants in various European and
African countries, and millions of children have been exposed to
these drugs, despite a lack of evidence of efficacy as shown by the
Cochrane database systematic review and strong warnings on
safety [12–16]. Detailed data on the ADRs that led to the
withdrawal of the license in France could help parents (because
these drugs are over-the-counter drugs), physicians, pharmacists,
and drug regulatory agencies precisely evaluate the benefit risk
ratio of these drugs. We aimed to analyze cases of respiratory
ADRs during the use of mucolytic drugs in children, particularly
infants, voluntarily reported by physicians in France.
Methods
General methodology
The study followed the recommendations of the European
Guidelines of pharmacovigilance for medicines used in the
paediatric population [17], the guidelines for submitting adverse
events reports for publication [18], and the French pharmacov-
igilance practice guidelines [19]. We analyzed all cases of
respiratory paradoxical ADRs (as described below) concerning
carbocysteine and acetylcysteine voluntarily reported from 1989 to
2008 to the French pharmacovigilance system. In France,
physicians and pharmacists must report all potential ADRs to
public regional centers of pharmacovigilance or national drug
company pharmacovigilance centers using pre-define forms [20].
The forms are completed anonymously and contain data on age,
weight, medical history of the patient, drug exposure, and the side
effect reported (type, severity, co-treatments received). Cases are
then analyzed by pharmacologists; additional data can be collected
from the declaring physicians or pharmacists before the file is
validated and included anonymously in the national database or
the drug company databases.
For the present study, the case identification strategy involved
use of the national pharmacovigilance website ARIS g5 (contain-
ing cases reported to regional centers of pharmacovigilance) and
reports by the industry of any case of ADR involving carbocysteine
and acetylcysteine during the national survey conducted after a
commitment of the French drug agency [14], with an age limit of 0
to 6 years. We hand-searched results and excluded cases of non-
respiratory ADR.
Cases
Our investigation focused on potential ADRs reported in the
literature [13] or described in the warning report [14] of the
French drug agency: worsening of a respiratory disease (during
bronchitis, bronchiolitis, or pneumonia), increased bronchorrhea
during acute cough, mucus vomiting, dyspnea, prolonged cough,
and bronchospasm. We included all cases whatever the medical
history or chronic underlying disease.
Exposure definition
In France, until April 2010, 42 formulations of carbocysteine (in
syrup or powder) and 15 of acetylcysteine were licensed for use in
paediatric patients from 1 month of age. These drugs are to be
absorbed by an oral route, and no license exists for the nebulized
route of administration. For carbocysteine, the recommended
dosage for children from 1 month to 2 years is 20 to 30 mg/kg/
day divided into 2 to 3 intakes. For children from 2 to 5 years old,
the recommended dosage is 100 mg twice a day and for those
older than 5 years, 100 mg 3 times a day. For acetylcysteine, the
recommended dosage is 100 mg twice a day for infants from 1
month to 2 years old and 200 mg twice a day for children older
than 2 years. The duration of the treatment should not exceed 8 to
10 days without medical advice [21].
For the present study, patients were arbitrarily considered
exposed to mucolytic drugs if they had received carbocysteine or
acetylcysteine for at least 2 days (.200 mg) and at least until the
day before the first signs of the suspected ADR.
Analysis
We first described the population of patients included in the
study, then analyzed the indications of the prescription, the
exposure to mucolytic drugs, the potential ADRs reported and
their evolution, then co-treatments received.
Ethics
The Institutional Review Committee (Comite ´ de Protection des
Personnes Ile de France III) approved this study. Written informed
consent of the patients or their parents was not possible for this
kind of study based on anonymous data. The waiver of consent
was approved by the Institutional Review Committee (Comite ´d e
Protection des Personnes Ile de France III).
Results
During the study period, 1989 to 2008, 139 cases of ADRs in
children (all younger than 6 years) potentially due to mucolytic
drug exposure were reported to public regional centers of
pharmacovigilance or to drug companies. We excluded 69 reports
of non-respiratory ADRs and 11 of respiratory ADRs with a total
drug exposure ,200 mg. Thus, the study analyzed the data for 59
cases of respiratory ADR in children younger than 6 years after an
exposure of .200 mg to mucolytic drugs. Seven cases had been
reported to drug companies, the 52 other cases had been reported
to 6 regional centers of pharmacovigilance throughout France.
Among the 59 cases, 46 cases (78%) were reported in the last 7
years (2002–2008) of the study period. The mean age of children
was 8.6 months (median age 5 months, range 3 weeks to 34
months): 6 children (10%) were neonates, 34 (58%) were younger
than 6 months, 46 (78%) were younger than 1 year old, and 11
(19%) were between 1 and 2 years old, and one child was older
than 2 years. The mean weight was 7.9 kg (median 7 kg, range
3.1–18 kg). One patient had a severe underlying condition
(broncho-pulmonary dysplasia); 9 children (15%) had a relevant
medical history prior to the current episode that led to mucolytic
drug use: bronchiolitis (n=8, 14%), asthma (n=1).
At the time of the mucolytic drug use, the non-exclusive
symptoms or diagnoses were cough (n=28, 47%), rhinitis (n=14,
24%), rhinopharyngitis (n=8, 14%), bronchiolitis (n=8, 14%),
bronchitis (n=7, 12%), dyspnoea (n=6, 10%), bronchorrhea
(n=4, 7%), tracheitis (n=1), pleuropneumonia (n=1), and fever
(n=1).
Thirty patients (51%) received carbocysteine and 28 (48%)
acetylcysteine, and one child received the 2 drugs simultaneously.
No child was exposed to a drug combination such as carbocys-
teine–promethazine. The mean duration of mucolytic treatment
before the beginning of the ADR was 5.9 days (median 4 days;
range 2–39 days). All children received oral treatment. Four
children (7%) received this treatment without a prescription (i.e.,
over-the-counter drug). For carbocysteine, the mean dosage was
181 mg per day (median 200 mg; range 100–300 mg), which
represented a mean of 23 mg/kg per day (median 23 mg/kg;
range 8–54 mg/kg). For acetylcysteine, the mean drug regimen
was 182 mg per day (median 200 mg; range 100–400 mg) and
27 mg/kg per day (median 22 mg/kg; range 8–65 mg/kg).
Patients younger than 6 months received a mean drug regimen
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older children.
The non-exclusive respiratory ADRs reported were worsening
of respiratory distress during bronchiolitis (n=35, 59%), increased
bronchorrhea (n=19, 32%), dyspnoea (n=18, 31%), cough
aggravation or prolongation (n=11, 19%), mucus vomiting
(n=8, 14%), pneumonia (n=3, 5%), acute bronchitis (n=2,
3%), and bronchospasm (n=1).
Fifty-one children (86%) required hospitalization or extended
hospitalization because of the ADR. Mucolytic drug treatment was
withdrawn for all patients. Oxygenotherapy was required for 18
children (31%); 12 (20%) received antibiotics, 9 (15%) corticoste-
roids for asthma crisis, and 11 (19%) inhaled b2 agonists.
Evolution was favorable in all cases except for one patient in
whom pleuropneumonia developed and a 1-year-old girl who died
of pulmonary oedema that was considered secondary to mucus
vomiting according to the reporting physician.
During the same window of exposure as that chosen for
mucolytic drugs, 21 children (36%) had received corticosteroids,
21 (36%) antibiotics, 12 (20%) inhaled b2 agonists, 11 (19%)
acetaminophen, 5 (8%) ibuprofen, 4 (7%) domperidone, one
helicidine, one oxomemazine and guaifenesine, and 3 (5%)
antihistamine (ketotifen, mequitazine, chlorphenamine).
Discussion
This study is the first to analyze cases of respiratory ADRs
associated with the systemic use of carbocysteine and acetylcys-
teine in children that were reported to the pharmacovigilance
reporting system. We identified 59 cases of worsening of a
respiratory disease increased bronchorrhea during acute cough,
dyspnoea, prolonged cough, mucus vomiting, and bronchospasm.
These cases were severe: 51 patients (86%) required hospitaliza-
tion or extended hospitalization, and 1 patient died.
The literature provides a hypothesis to explain the mechanisms
by which use of mucolytic drugs during acute respiratory tract
infections in infants may be associated with respiratory ADRs [12–
16]. The anatomical and physiological specificities of the airways
of infants – numerous mucus glands, small bronchial diameter,
muscular immaturity – predispose this age group to this kind of
ADR [22]. During infection, the modifications of the airway (i.e.,
bronchorrhea, reduced bronchial diameter, inflammation) en-
hance this predisposition. The increase in bronchial mucus flow
induced by mucolytic drugs could exceed the ability for
spontaneous drainage in the infant and then induce prolonged
cough and worsened respiratory distress during acute airway
infection. Interestingly, this kind of respiratory ADR was
mentioned early in reviews [23,24] and pharmacological textbooks
[25,26] but was not clinically documented or declared to the
pharmacolovigilance system.
Despite these strong pathophysiological bases, a causal
relationship would be difficult to definitively prove in these
cases of respiratory paradoxical ADRs associated with the
systemic use of carbocysteine and acetylcysteine in pediatric
patients because of the potential presence of a protopathic bias.
Protopathic bias can occur when the first symptoms of the
potential ADR can induce treatment. This bias could be present
with respiratory ADRs associated with the systemic use of
carbocysteine and acetylcysteine in pediatric patients. The only
way to evaluate the paradoxical side effects of drugs and avoid
protopathic bias would be theoretically to study them in another
unrelated disease [13]. However, this is not possible in the case
of carbocysteine because its only indications are respiratory
tract infections. For acetylcysteine, data from a multicenter
postmarketing safety study including 1905 pediatric patients
receiving acetylcysteine for acetaminophen overdose between
1980 and 2005 are consistent with this hypothesis of paradoxical
side effects [27]. Indeed, in this study where patients did not
receive acetylcysteine to treat respiratory tract infection, the
incidence of respiratory ADRs (such as bronchospasm, cough,
wheezing, or respiratory distress) was 2.2% [27]. Thus, the level
of evidence of the respiratory paradoxical ADRs associated with
the systemic use of carbocysteine and acetylcysteine in pediatric
patients will probably stay limited to experts’ opinion and strong
pathophysiological bases.
That young infants are more affected than older ones by
respiratory ADRs associated with the systemic use of carbocysteine
and acetylcysteine seems to have 2 explanations. First, the
pediatric anatomical particularities described previously are more
important in the youngest infants. Second, the dosage proposed in
the license for acetylcysteine indicates a single dose for children
from 1 to 24 months whatever the weight of the child. According
to World Health Organization standards, the median weight at 1
month and 2 years is 4.5 and 12.2 kg, respectively [28]. A single
dose regimen for children from 1 to 24 months induces a different
regimen per weight (44.4 vs. 16.4 mg/kg/day) and exposes the
youngest infants to higher doses, as was observed in our study.
Thus, a dose-related effect could explain the age distribution of the
reported cases of respiratory ADRs.
We could not evaluate the frequency of respiratory ADRs
among pediatric patients. Safety data from clinical studies
performed by drug companies did not identify these respiratory
ADRs [13]. However, the power of the efficacy studies was limited
by the small number of patients included (n,152) and the very
small number of infants included (n,29) [13]. The power of the
unique study designed to evaluate safety was low (n=20), and this
study included few infants [29]. The total number of ADRs we
describe could seem low as compared with the huge extent of the
exposure of the pediatric population to these drugs. However, the
lack of exhaustiveness of a spontaneous reporting system for ADRs
is well known. Begaud et al. showed only 5% of severe ADRs
leading to the hospitalization of patients reported in France [30].
Thus, the exact number of respiratory ADRs that occur in the
population could be much higher than that reported and analyzed
in this survey. For example, a 2-month prospective study
performed in the emergency department of 2 pediatric teaching
hospitals in Paris, France, identified 6 cases [12,13]. The
frequency of respiratory ADR was not calculated in the present
study and is most probably very low. However, it does not modify
the evaluation of the benefit risk ratio of these drugs for which
there is a complete lack of evidence of efficacy as shown by the
Cochrane database systematic review [13].
In conclusion, carbocysteine and acetylcysteine are still licensed
and largely used for children younger than 2 years in many
European, South-American and African countries, despite a
clearly demonstrated lack of evidence of efficacy and a strong
warning on safety as reported in this study and others [12–16].
Thus, parents, physicians, pharmacists, and drug regulatory
agencies should know that the benefit risk ratio of these drugs is
at least null and most probably negative in this age group
according to available evidence.
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